Jefferies on BridgeBio Pharma (BBIO): expecting Attruby sales to beat consensus estimates
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $100.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst commented, "For ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
